Decreased TET2 gene expression during chronic myeloid leukemia progression

被引：31
作者：
Albano, F. [1 ]
Anelli, L. [1 ]
Zagaria, A. [1 ]
Coccaro, N. [1 ]
Minervini, A. [1 ]
Rossi, A. Russo [1 ]
Specchia, G. [1 ]
机构：
[1] Univ Bari, I-70124 Bari, Italy
来源：
LEUKEMIA RESEARCH | 2011年 / 35卷 / 11期
关键词：
Chronic myeloid leukemia; TET2; Microdeletion; MYELOPROLIFERATIVE NEOPLASMS; PROGNOSTIC VALUE; CANCERS;
D O I：
10.1016/j.leukres.2011.07.013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recently it has been demonstrated that ten-eleven-translocation-2 (TET2) gene alterations may represent a crucial event in the pathogenesis of various myeloid malignancies. To date, the loss of TET2 function has been solely ascribed to mutations in the gene coding region. In this study, we report a chronic myeloid leukemia (CML) case showing a TET2 single copy partial deletion associated to a t(4;6;11) rearrangement, appearing during the progression of the disease and responsible for a decreased TET2 gene expression. A putative role for TET2 haploinsufficiency in this patient's CML progression is discussed. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码：E220 / E222
页数：3
相关论文
共 10 条
  • [1] Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias
    Abdel-Wahab, Omar
    Manshouri, Taghi
    Patel, Jay
    Harris, Kelly
    Yao, JinJuan
    Hedvat, Cyrus
    Heguy, Adriana
    Bueso-Ramos, Carlos
    Kantarjian, Hagop
    Levine, Ross L.
    Verstovsek, Srdan
    [J]. CANCER RESEARCH, 2010, 70 (02) : 447 - 452
  • [2] Downregulated expression of genes mapping on chromosome 9 in chronic myeloid leukemia cases bearing genomic deletions on der(9)
    Albano, F.
    Anelli, L.
    Zagaria, A.
    Pannunzio, A.
    Liso, V.
    Rocchi, M.
    Specchia, G.
    [J]. LEUKEMIA, 2009, 23 (04) : 813 - 816
  • [3] Home-brew FISH assay shows higher efficiency than BCR-ABL dual color, dual fusion probe in detecting microdeletions and complex rearrangements associated with t(9;22) in chronic myeloid leukemia
    Albano, Francesco
    Anelli, Luisa
    Zagaria, Antonella
    Archidiacono, Nicoletta
    Liso, Vincenzo
    Specchia, Giorgina
    Rocchi, Mariano
    [J]. CANCER GENETICS AND CYTOGENETICS, 2007, 174 (02) : 121 - 126
  • [4] Mutation in TET2 in Myeloid Cancers
    Delhommeau, Francois
    Dupont, Sabrina
    Della Valle, Veronique
    James, Chloe
    Trannoy, Severine
    Masse, Aline
    Kosmider, Olivier
    Le Couedic, Jean-Pierre
    Robert, Fabienne
    Alberdi, Antonio
    Lecluse, Yann
    Plo, Isabelle
    Dreyfus, Francois J.
    Marzac, Christophe
    Casadevall, Nicole
    Lacombe, Catherine
    Romana, Serge P.
    Dessen, Philippe
    Soulier, Jean
    Viguie, Franck
    Fontenay, Michaela
    Vainchenker, William
    Bernard, Olivier A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (22) : 2289 - 2301
  • [5] Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
    Ko, Myunggon
    Huang, Yun
    Jankowska, Anna M.
    Pape, Utz J.
    Tahiliani, Mamta
    Bandukwala, Hozefa S.
    An, Jungeun
    Lamperti, Edward D.
    Koh, Kian Peng
    Ganetzky, Rebecca
    Liu, X. Shirley
    Aravind, L.
    Agarwal, Suneet
    Maciejewski, Jaroslaw P.
    Rao, Anjana
    [J]. NATURE, 2010, 468 (7325) : 839 - 843
  • [6] TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)
    Kosmider, Olivier
    Gelsi-Boyer, Veronique
    Cheok, Meyling
    Grabar, Sophie
    Della-Valle, Veronique
    Picard, Francoise
    Viguie, Franck
    Quesnel, Bruno
    Beyne-Rauzy, Odile
    Solary, Eric
    Vey, Norbert
    Hunault-Berger, Mathilde
    Fenaux, Pierre
    Mansat-De Mas, Veronique
    Delabesse, Eric
    Guardiola, Philippe
    Lacombe, Catherine
    Vainchenker, William
    Preudhomme, Claude
    Dreyfus, Francois
    Bernard, Olivier A.
    Birnbaum, Daniel
    Fontenay, Michaela
    [J]. BLOOD, 2009, 114 (15) : 3285 - 3291
  • [7] CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia
    Makishima, Hideki
    Jankowska, Anna M.
    McDevitt, Michael A.
    O'Keefe, Christine
    Dujardin, Simon
    Cazzolli, Heather
    Przychodzen, Bartlomiej
    Prince, Courtney
    Nicoll, John
    Siddaiah, Harish
    Shaik, Mohammed
    Szpurka, Hadrian
    Hsi, Eric
    Advani, Anjali
    Paquette, Ronald
    Maciejewski, Jaroslaw P.
    [J]. BLOOD, 2011, 117 (21) : E198 - E206
  • [8] Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission
    Nibourel, Olivier
    Kosmider, Olivier
    Cheok, Meyling
    Boissel, Nicolas
    Renneville, Aline
    Philippe, Nathalie
    Dombret, Herve
    Dreyfus, Francois
    Quesnel, Bruno
    Geffroy, Sandrine
    Quentin, Samuel
    Roche-Lestienne, Catherine
    Cayuela, Jean-Michel
    Roumier, Christophe
    Fenaux, Pierre
    Vainchenker, William
    Bernard, Olivier A.
    Soulier, Jean
    Fontenay, Michaela
    Preudhomme, Claude
    [J]. BLOOD, 2010, 116 (07) : 1132 - 1135
  • [9] Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value
    Smith, Alexander E.
    Mohamedali, Azim M.
    Kulasekararaj, Austin
    Lim, ZiYi
    Gaeken, Joop
    Lea, Nicholas C.
    Przychodzen, Bartlomiej
    Mian, Syed A.
    Nasser, Erick E.
    Shooter, Claire
    Westwood, Nigel B.
    Strupp, Corinna
    Gattermann, Norbert
    Maciejewski, Jaroslaw P.
    Germing, Ulrich
    Mufti, Ghulam J.
    [J]. BLOOD, 2010, 116 (19) : 3923 - 3932
  • [10] Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
    Tefferi, A.
    [J]. LEUKEMIA, 2010, 24 (06) : 1128 - 1138
1